PRTG Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	174 049
Vidutinė apimtis	171 620
Rinkos kapitalizacija	5.45M
EPS	$0 ( 2024-05-14 )
Kita pelno data	( $-0.220 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.00500 (1.81%)

Tūris Koreliacija

Ilgas: 0.21 (neutral)

Trumpas: -0.13 (neutral)

Signal:(61.266) Neutral

Portage Biotech Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
FFIE	0.949
EVOK	0.944
NWFL	0.939
LGVN	0.939
INVZ	0.937
GLBS	0.937
TOPS	0.936
IMMX	0.936
VVOS	0.935
BPRN	0.933

10 Labiausiai neigiamai susiję koreliacijos
INBKZ	-0.925
ADTH	-0.908
APXI	-0.905
FLXS	-0.899
BSCO	-0.898
OXSQ	-0.892
SILK	-0.887
DXJS	-0.886
ESTA	-0.879
FSEA	-0.879

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Portage Biotech Inc. Koreliacija - Valiuta/Žaliavos

0.34
( neutral )

0.33
( neutral )

0.00
( neutral )

-0.28
( neutral )

Portage Biotech Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2023
Pajamos:	$0
Bruto pelnas:	$-1 000.00 (0.00 %)
EPS:	$-6.49

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.470

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.350

Financial Reports:

No articles found.

Portage Biotech Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.